(Albany, USA) DelveInsight’s “Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Atopic Dermatitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Atopic Dermatitis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Atopic Dermatitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Atopic Dermatitis market.
Request for sample page @ Atopic Dermatitis Market Forecast
Key Takeaways from the Atopic Dermatitis Market Report
- According to DelveInsight, Atopic Dermatitis market size is expected to grow at a decent CAGR by 2032.
- Leading Atopic Dermatitis Companies in the treatment market Sanofi/Regeneron Pharmaceuticals, RAPT Therapeutics, Pfizer, Japan Tobacco, and Torii Pharmaceutical, Eli Lilly and Company, AbbVie, LEO Pharma, Incyte Corporation, Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen, AOBiome Therapeutics, Kymab, Qurient, Arcutis Biotherapeutics, Cara Therapeutics, Vanda Pharmaceuticals, and others.
- Promising Atopic Dermatitis Pipeline Therapies include Baricitinib, Dupilumab, Lebrikizumab, and others.
- The total prevalent cases of Atopic Dermatitis in the United States were around 32,573,900 cases in 2022.
- Approximately 60–70% of diagnosed Atopic dermatitis cases are mild, whereas ~30% are moderate-to-severe.
- In June 2023, RAPT Therapeutics announced A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults with Moderate-to-Severe Atopic Dermatitis.
- In Feb 2023, Shulov Innovate for Science Ltd announced a phase II, double blind study with ZEP-3NA 0.1% or 1% vs. vehicle-control in subjects with mild to moderate Atopic Dermatitis. The IP (Investigational Product) will be administered topically twice daily for 4 weeks in the double blind phase. patients that will reach the primary endpoint will have the opportunity for additional to two weeks of open label treatment with ZEP-3Na 1%.
- In Dec 2022, Q32 Bio Inc. announced a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
Atopic Dermatitis Overview
Atopic dermatitis, also known as eczema, is a chronic skin condition characterized by inflamed, itchy, and dry skin. It commonly affects children and may persist into adulthood. The exact cause is unknown, but it is believed to be a combination of genetic and environmental factors. Symptoms include red, patchy, and scaly skin that can become thickened or cracked. Treatment aims to relieve symptoms and prevent flare-ups, typically involving moisturizers, topical corticosteroids, and antihistamines. Lifestyle modifications, such as avoiding triggers and maintaining proper skin care, can also help manage the condition. Consultation with a healthcare professional is recommended for diagnosis and personalized treatment.
Atopic Dermatitis Epidemiology Segmentation
- Atopic Dermatitis Prevalent Population
- Diagnosed Prevalent Population of Atopic Dermatitis
- Severity-specific Distribution of Atopic Dermatitis in Adults
- Severity-specific Distribution of Atopic Dermatitis in Pediatric Population
- Gender-specific Distribution of Atopic Dermatitis in Adults
- Chronic Pruritus Prevalence in Atopic Dermatitis in the adults
Download the report to understand which factors are driving Atopic Dermatitis epidemiology trends @ https://www.delveinsight.com/sample-request/atopic-dermatitis-market
Atopic Dermatitis Emerging Drugs
Rocatinlimab (KHK4083/AMG 451): Amgen/Kyowa Kirin
Rocatinlimab (KHK4083/AMG 451) is an anti-OX40 human monoclonal antibody that inhibits and reduces the number of OX40-expressing pathogenic T cells responsible for driving systemic and local inflammatory responses. It has been reported that effector T cells expressing OX40 are present in the lesions of patients with Atopic Dermatitis and are critical in the disease pathophysiology. The initial antibody was discovered in collaboration between Kyowa Kirin US Research and La Jolla Institute for Immunology.
Amgen and Kyowa Kirin have recently begun recruiting participants for a comprehensive, global Phase III program (ROCKET program) to investigate the safety and efficacy of rocatinlimab in a heterogeneous moderate-to-severe AD population suffering from a high burden of disease.
Atopic Dermatitis Market Dynamics
Atopic Dermatitis market to expand because of the emergence of several novel mechanisms such as oral/topical JAK Inhibitors, PDE Inhibitors, IL-13 Inhibitors, leukotriene inhibitors, Kappa opioid receptor (KOR) agonist, NK-1 receptor antagonist, and others in the upcoming market of Atopic Dermatitis and pruritus in Atopic Dermatitis. Increased public awareness, improved access to health services, reimbursements, and financial support may boost the Atopic Dermatitis and pruritus in the market and improve the Atopic Dermatitis market accessibility of the emerging drugs.
To know more about Atopic Dermatitis Treatment options, visit @ https://www.delveinsight.com/sample-request/atopic-dermatitis-market
Atopic Dermatitis Pipeline Companies
The developing pipeline of Atopic Dermatitis holds budding key players such as lebrikizumab (Eli Lilly), nemolizumab/CD14152 (Galderma), difamilast (Otsuka Pharmaceuticals), and roflumilast (Arcutis Biotherapeutics). These emerging drugs, predicted to be launched during the forecast period, are likely to change the current market dynamics of disease treatment, thereby boosting the current Atopic Dermatitis market size. Following the late-stage products, a wide array of mid-stage or Phase II promising interventions are expected to be launched soon in the Atopic Dermatitis market, including B244 (AOBiome Therapeutics), etrasimod/APD334 (Arena Pharmaceuticals), FB825 (Oneness Biotech), DS107 (DS Biopharma), bermekimab (Janssen), KY1005 (Sanofi/Kymab), and Q301 (Zileuton) (Qurient).
Learn more about the Atopic Dermatitis Pipeline Therapies in clinical trials @ https://www.delveinsight.com/sample-request/atopic-dermatitis-market
Scope of the Atopic Dermatitis Pipeline Report
- Coverage- 7MM
- Atopic Dermatitis Companies- Sanofi (NYSE: SNY), Regeneron Pharmaceuticals (NYSE: REGN), Pfizer (NYSE: PFE), Japan Tobacco, Torii Pharmaceutical (NYSE: TRXPF), Eli Lilly and Company (NYSE: LLY), AbbVie (NYSE: ABBV), LEO Pharma, Incyte Corporation (NYSE: INCY), Arena Pharmaceuticals, Oneness Biotech, Galderma, DS Biopharma, Janssen (NYSE: JNJ), AOBiome Therapeutics, Kymab, Qurient (NYSE: KRX), Arcutis Biotherapeutics (NYSE: ARQT), Cara Therapeutics (NYSE: CARA), Vanda Pharmaceuticals (NYSE: VNDA), and others.
- Atopic Dermatitis Pipeline Therapies include Baricitinib, Dupilumab, Lebrikizumab, and others.
- Atopic Dermatitis Market Dynamics: Atopic Dermatitis Market Drivers and Barriers
Discover more about Atopic Dermatitis Drugs in development @ Atopic Dermatitis Ongoing Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/atopic-dermatitis-market
Table of Content
- Key Insights
- Atopic Dermatitis Report Introduction
- Atopic Dermatitis (AD) Market Overview at a Glance
- Epidemiology and Market Methodology
- Executive Summary
- Atopic Dermatitis Disease Background and Overview
- Atopic Dermatitis Epidemiology and Patient Population
- Atopic Dermatitis Patient Journey
- Key Endpoints in Atopic Dermatitis Clinical Trials
- Atopic Dermatitis Marketed Therapies
- Atopic Dermatitis Emerging Therapies
- Atopic Dermatitis (Atopic Dermatitis): The 7MM Analysis
- Atopic Dermatitis Market Access and Reimbursement
- Atopic Dermatitis KOL Views
- Atopic Dermatitis SWOT Analysis
- Atopic Dermatitis Unmet Needs
- Appendix
- DelveInsight Capabilities
- Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting